-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
With Kintor Pharmaceutical Limited's (HKG:9939)) Price Down 28% This Week, Insiders Might Find Some Solace Having Sold CN¥71m Worth of Shares Earlier This Year.
With Kintor Pharmaceutical Limited's (HKG:9939)) Price Down 28% This Week, Insiders Might Find Some Solace Having Sold CN¥71m Worth of Shares Earlier This Year.
Insiders at Kintor Pharmaceutical Limited (HKG:9939) sold CN¥71m worth of stock at an average price of CN¥20.35 a share over the past year, making the most of their investment. The company's market worth decreased by HK$2.0b over the past week after the stock price dropped 28%, although insiders were able to minimize their losses
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
Check out our latest analysis for Kintor Pharmaceutical
Kintor Pharmaceutical Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider sale was by the insider, Chuangxing Guo, for HK$60m worth of shares, at about HK$19.93 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (HK$13.42). So it is hard to draw any strong conclusion from it.
All up, insiders sold more shares in Kintor Pharmaceutical than they bought, over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
SEHK:9939 Insider Trading Volume September 6th 2022If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
Insiders At Kintor Pharmaceutical Have Sold Stock Recently
The last three months saw significant insider selling at Kintor Pharmaceutical. In total, CFO, Joint Company Secretary & Executive Director Yan Lu dumped HK$11m worth of shares in that time, and we didn't record any purchases whatsoever. Overall this makes us a bit cautious, but it's not the be all and end all.
Insider Ownership
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Kintor Pharmaceutical insiders own about HK$1.2b worth of shares (which is 24% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
What Might The Insider Transactions At Kintor Pharmaceutical Tell Us?
An insider sold Kintor Pharmaceutical shares recently, but they didn't buy any. Zooming out, the longer term picture doesn't give us much comfort. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we found 4 warning signs for Kintor Pharmaceutical that deserve your attention before buying any shares.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
业内人士在金达药业有限公司(HKG:9939)在过去一年中以每股20.35元的平均价格出售了价值7100万加元的股票,充分利用了他们的投资。在股价下跌28%后,该公司市值在过去一周缩水20亿港元,尽管内部人士能够将损失降至最低
尽管就长期投资而言,内幕交易并不是最重要的事情,但我们确实认为,密切关注内部人士的所作所为是完全合乎逻辑的。
查看我们对Kintor制药公司的最新分析
Kintor制药公司去年的内幕交易
过去一年,我们可以看到,最大的内幕交易是内部人士郭创兴以每股19.93港元的价格收购了价值6000万港元的股票。虽然内幕出售是负面的,但对我们来说,如果股票以更低的价格出售,负面影响就更大。一线希望是,此次抛售发生在最新股价(13.42港元)之上。因此,很难从中得出任何强有力的结论。
总的来说,在过去的一年里,内部人士卖出的Kintor Pharmtics股票多于他们买入的股票。你可以在下面看到过去12个月(由公司和个人)进行的内幕交易的直观描述。如果你点击图表,你可以看到所有的个人交易,包括股票价格、个人和日期!
联交所:9939内幕交易量2022年9月6日如果你像我一样,你会的不想怀念这一切吗?免费内部人士正在收购的成长型公司名单。
Kintor制药的内部人士最近抛售了股票
在过去的三个月里,Kintor制药公司出现了大量的内幕销售。董事首席财务官兼联席公司秘书兼执行董事陆岩在那段时间总共抛售了价值1100万港元的股票,我们没有记录任何买入。总体而言,这让我们有点谨慎,但这并不是一切。
内部人持股
许多投资者喜欢查看一家公司有多少股份是由内部人士持有的。通常,内部人持股越高,内部人就越有可能受到激励,建立长期的公司。Kintor Pharmtics的内部人士持有价值约12亿港元的股份(占公司股份的24%)。大多数股东将乐于看到这种内部人持股,因为这表明管理层的激励与其他股东很好地结合在一起。
Kintor制药公司的内幕交易可能告诉我们什么?
一位内部人士最近抛售了Kintor Pharmtics的股票,但他们没有买入任何股票。缩小来看,较长期的图景并不会给我们带来太多安慰。虽然内部人士确实持有该公司的大量股份(这很好),但我们对他们交易的分析并不能让我们对该公司充满信心。虽然我们喜欢知道内部人士的所有权和交易情况,但在做出任何投资决定之前,我们也要确保考虑到一只股票面临的风险。在Simply Wall St.,我们发现Kintor制药公司的4个警告信号在购买任何股票之前,这些都值得你关注。
当然了,如果你把目光投向别处,你可能会发现这是一笔很棒的投资。所以让我们来看看这个免费有趣的公司名单。
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧